Close Menu

CareDx: Kashif Rathore, Ryan Phan, Sean Grant, and Danielle Scelfo

Sep 10, 2020

CareDx has appointed Kashif Rathore as senior VP of digital business, Ryan Phan as VP of lab operations, Sean Grant as VP of strategy and business development, and Danielle Scelfo as VP of market access and health policy.

Rathore joins CareDx from Cerner, where he held various senior leadership roles. In addition to his most recent role as VP of interoperability, Rathore served in the consulting and technology lines of Cerner's businesses. 

Phan joins CareDx from Kaiser Permanente, where he served as managing director and head of regional molecular genetics and cytogenetics laboratories. He has led multiple strategic laboratory expansions and developed and implemented clinical testing programs. 

Grant joins CareDx from Citigroup Global Capital Markets, where he served as a VP in the investment banking healthcare division. At Citigroup, Grant specialized in raising public and private capital and executed a broad range of transactions, including M&A, for many life sciences companies around the world. 

Scelfo joins CareDx from Hologic, where she served as senior director of health policy and reimbursement. She has more than 25 years of health policy and strategic market access experience, including roles at Genomic Health and Adaptive Biotechnologies.

More Like This

Oct 29, 2020

CareDx: Peter Maag, Reginald Seeto

CareDx announced that current Chairman and CEO Peter Maag will assume the role of executive chairman of the board, effective Nov. 1, and that current President and Chief Business Officer (CBO) Reginald Seeto will then assume the role of president and CEO. Seeto will also join the company's board.

Maag joined CareDx in 2012 as CEO and led the company through its IPO. Seeto joined CareDx in 2018 as president and CBO, leading the company's commercial, clinical, manufacturing, and R&D organizations. 

Oct 29, 2020

Prime Genomics: Robert Weigle

Prime Genomics, a company developing noninvasive testing to improve breast cancer detection, has named Robert Weigle as CEO. Weigle joins the firm from DigitalDx Ventures where he was an entrepreneur in residence. He has previously held senior-level sales and marketing positions at Johnson & Johnson, Baxter, and several startup ventures.

Oct 29, 2020

Qiagen: Jean-Pascal Viola

Qiagen has appointed Jean-Pascal Viola as senior vice president, head of the molecular diagnostics business area, in addition to his current role as leader of corporate business development and intellectual property and litigation, which he assumed in 2015. Viola will also continue to serve as a member of Qiagen's executive committee. He joined Qiagen in 2005 and has held various roles in Singapore, the US, and Germany. Since joining the business development team in 2007, he played a leading role in the acquisitions of Cellestis, Stat-Dx, NeuMoDx, and the assets of Forumlatrix related to digital PCR.

Oct 29, 2020

Clear Labs: Jeff Field

Clear Labs has hired Jeff Field to be its chief commercial officer. He has more than two decades of experience in healthcare and formerly was CCO at IDbyDNA and VP of oncology at Foundation Medicine. At Clear Labs, Field will oversee the continued commercialization of the company's tests including Clear Safety and Clear Dx nationally and internationally.

Oct 27, 2020

Inscripta: Sri Kosaraju

Inscripta has appointed Sri Kosaraju as its new president and CEO. Kosaraju succeeds Kevin Ness, who was the company's CEO since 2016, and who will remain as an advisor.

Kosaraju currently serves on the board of directors and is the chair of the Audit Committee of 10x Genomics. He also serves on the board of the non-profit Testing for America. Prior to joining Inscripta, Kosaraju was president of Penumbra, and spent 16 years at JP Morgan, where he most recently served as head of Healthcare Equity Capital Markets and co-head of Technology Equity Capital Markets. 

Oct 23, 2020

Becton Dickinson: John DeFord, Patrick Kaltenbach, Dave Hickey

Becton Dickinson announced the retirement of Chief Technology Officer John DeFord, who joined BD with the acquisition of CR Bard in 2017. DeFord will be succeeded by Patrick Kaltenbach, who will serve as CTO and executive vice president. Kaltenbach joined BD as president of the life sciences segment in May 2018 after having most recently served as Agilent's senior vice president and president of that firm's life sciences and applied markets group. Dave Hickey, who currently serves as BD's worldwide president of integrated diagnostics solutions, will be promoted to the position of executive vice president and president of life sciences. The new appointments will be effective Jan. 1, 2021.

Oct 23, 2020

Biocept: Samuel Riccitelli

Biocept has appointed Samuel Riccitelli to its board of directors, effective immediately, and ahead of the planned retirement of Bruce Huebner, who will leave the board on Nov. 30, 2020Riccitelli boasts 35 years of experience in the molecular diagnostics industry, having served in executive-level positions and on the boards of multiple publicly traded companies. At Biocept, he will initially serve on the audit committee and the science and technology committee.

Riccitelli currently serves as an independent consultant to healthcare companies and is a director of OrthoPediatrics, a company focused on the orthopedic implant needs of children. Prior to that he was CEO of Pathnostics, a molecular diagnostics company focused on improving antibiotic stewardship. He also served as chairman of Precipio; president, CEO, and director of Signal Genetics; and executive VP and chief operating officer of Genoptix. Riccitelli received a BA from Washington and Jefferson College and an MS in engineering from The University of Texas.

Oct 08, 2020

Caris Life Sciences: Brian Lamon

Caris Life Sciences has appointed Brian Lamon as its chief business officer and head of biopharma business development. Lamon brings over 15 years of experience from large pharma and academia to the firm. He previously worked for Bristol Myers Squibb as a VP and development lead. Prior to that, he held several leadership roles in clinical development and business development for the same company.

Before joining industry, Lamon was assistant dean of research development and an assistant professor in the department of pathology and laboratory medicine at Weill Medical College of Cornell University in New York. He remains active on the faculty through a courtesy appointment as assistant professor.

Oct 07, 2020

New England Biolabs: Donald Comb

New England Biolabs founder Donald Comb has died. He founded NEB, one of the first biotechnology firms to commercialize restriction enzymes, in 1974 and served as its CEO until 2005, after which he remained chairman of the board of directors. Prior to NEB, he was a faculty member at Harvard Medical School. Comb held a PhD in biochemistry from the University of Michigan.

Oct 07, 2020

Nobel Prize: Emmanuelle Charpentier, Jennifer Doudna

Emmanuelle Charpentier and Jennifer Doudna have been jointly awarded the 2020 Nobel Prize in chemistry for their discovery and development of the CRISPR/Cas9 genome editing method.

"There is enormous power in this genetic tool, which affects us all. It has not only revolutionized basic science, but also resulted in innovative crops and will lead to ground-breaking new medical treatments," said Nobel Committee for Chemistry Chair Claes Gustafsson in a statement.

Charpentier is the director of the Max Planck Unit for the Science of Pathogens in Berlin. She holds a PhD from the Institute Pasteur in France.

Doudna is a professor at the University of California, Berkeley, and a Howard Hughes Medical Institute investigator. She holds a PhD from Harvard Medical School.

The two Nobel laureates will equally share the 10 million Swedish kronor ($1.12 million) award.

Oct 06, 2020

Pillar Biosciences: Robert Forrester

Pillar Biosciences, a next-generation sequencing cancer diagnostics company, has added Robert Forrester as an independent board member. Forrester has previously served as CEO of Verastem Oncology, COO of Forma Therapeutics, CEO and CFO of CombinatoRx, and CFO of Coley Pharmaceutical. He is also cofounder and chief experience officer of EQRx, which makes innovative medicines at dramatically lower prices for the benefit of society. Forrester has also served as managing director of the Proprietary Investment Group at MeesPierson.

Oct 06, 2020

Helio Health: Wei Li

Helio Health has appointed Wei Li to its advisory board. Li has more than 20 years of experience in bioinformatics research and development and is currently the endowed chair and professor of bioinformatics for the biological chemistry department at the University of California, Irvine's School of Medicine. He previously was the Dan L. Duncan Chair professor in the division of biostatistics at the Dan L. Duncan Cancer Center as part of the molecular and cellular biology department at the Baylor College of Medicine.

Oct 06, 2020

Karius: Alexander Ford

Karius has appointed Alexander (Alec) Ford as CEO. Ford most recently served as chief operating officer of Myriad Genetics. He will replace current CEO Mickey Kertesz, who will transition to the roles of president and chief product officer.

Oct 05, 2020

Myriad Genetics: Alexander Ford

Myriad Genetics said in a filing with the US Securities and Exchange Commission that Alexander Ford has resigned as chief operating officer as of Oct. 2. Before recently becoming chief operating officer, he was president of Myriad's women's health division and president of Myriad Genetic Laboratories. Prior to joining Myriad in 2010, Ford worked in various leadership roles in sales, business development, and product marketing at Novartis, Sanofi Aventis, Nektar Therapeutics, and Pfizer.

Oct 02, 2020

Oxford Nanopore Technologies: Guy Harmelin

Guy Harmelin has been appointed as a non-executive director of Oxford Nanopore Technologies, effective September 17. Previously, he was on the leadership team at Harel Insurance Investments and Financial Services, the largest insurance group in Israel. Prior to that, he was the cofounder and CEO of RondinX, a computational microbiome analysis company that was acquired by BiomX in 2017. Harmelin holds an MD from the University of Florence in Italy. 

A 50-year-old cold case was cracked using genetic genealogy, the New York Times reports.

NPR reports that some insect pests are now becoming resistant to Bt crops.

Science reports the US Food and Drug Administration did not consult an outside panel in its approval of remdesivir as a COVID-19 treatment.

In Nature this week: a framework for future human genomic research, PORE-cupine approach to study RNA structure using nanopore sequencing, and more.

Nov
03
Sponsored by
Agilent

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Sponsored by
Roche

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
10
Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.

Nov
18
Sponsored by
Genomenon

Rapid whole-genome sequencing (rWGS) is an emerging method that can provide molecular diagnosis in time to alter acute medical or surgical management and improve outcomes in acutely ill children.